Logo: to the web site of Uppsala University

Laboratory results play a big role in patient diagnosis. Thus, their accuracy is important, and it can be regulated through external quality assessment (EQA). Equalis is a Swedish organisation that provides several programmes for EQA one of which is a program for point-of-care C-reactive protein (CRP), glucose and hemoglobin (Hb). One big provider of a CRP analyser has made changes to their test cassette which has caused Equalis current EQA material not to work on the CRP analyser. An optimization of a new EQA material is therefore needed. EDTA whole blood was treated with different concentrations of two glycolysis inhibitors: maleimide and sodium iodoacetate, to prevent the glucose concentration from reducing in the material over time. Tests were performed to evaluate the stability of glucose and the level of hemolysis in the material during a period of seven days. Analysis on the CRP analyser was performed to see if a result was produced for the EQA material. Results for the material treated with sodium iodoacetate had high levels of hemolysis, up to 14 g/L hemoglobin in plasma, which lead to the material being ruled out. The initial results for the material treated with maleimide was promising, although after further testing the glucose concentration was found not to be stable. This study did not produce an optimized EQA material for the Equalis program for point-of-care CRP, glucose and Hb but did show results that will be helpful in further testing and evaluation.